

# Insulin Resistance and Major Depression: Pathways to Precision Medicine

KATHLEEN WATSON PHD, ALAN SCHATZBERG MD, NATALIE RASGON MD PHD



Department of Psychiatry & Behavioral Health, Stanford School of  
Medicine

August 20<sup>th</sup>, 2022

Stanford University


# Major Depressive Disorder: Challenges of Effective Treatment

- 20.6% of US adults experience a depressive disorder in their lifetime ([Hasin](#))
- 50 - 60% of people with major depressive disorder do not respond adequately to antidepressant medication ([Rush](#)).
- Major Depressive Disorder (MDD) is complex in its biology, its genetics is challenging to define, and its symptoms vary by person. There may be depression subtypes.
- One subtype of depression might be the insulin-resistant subtype.

Share of the population with depression, 2016

Prevalence of depressive disorders in a given population. This is measured as the age-standardized prevalence, which assumes a constant age structure to compare between countries and through time. Figures attempt to provide a true estimate (going beyond reported diagnosis) of depression prevalence based on medical, epidemiological data, surveys and meta-regression modelling.


Our World  
in Data



2016 Map of Depression Prevalence

## Insulin Resistance

- Insulin resistance is a physiological state where insulin receptors have a diminished response to the presence of insulin. It can lead to type 2 diabetes.
- Insulin resistance can lead to the inability to utilize glucose in muscle, adipose, and several other tissues.
- Insulin resistance has been associated with several somatic disorders, including cardiovascular disease, chronic kidney disease, Alzheimer's disease, and major depressive disorder.



Insulin Protein

# Is There an Insulin Resistant Subtype of Depression?




"His insulin just kicked in!"

© 2008 Diabetes Health

## Study 1: Insulin Resistance and Depression Characteristics

- The Netherlands Study of Depression and Anxiety (NESDA) describes the course and consequences of depressive disorders among adults 18 - 65.
- We measured insulin resistance in 1,269 adults with current depression, remitted depression, and non-depressed controls in the Netherlands Study of Depression and Anxiety.
- We measured insulin resistance using three metrics: 1) triglyceride high-density lipoprotein (HDL) ratio; 2) fasting plasma glucose (FPG) (mmol/L), and waist circumference (cm).
- We measured depression symptoms using the Inventory of Depression Symptomatology. Scores range from 0 to 87, with a higher score indicating greater depression severity.

## Insulin Resistance was Positively Associated with Current Major Depressive Episode and Severity of Depression Symptoms




- Insulin resistance was positively associated with having current major depressive disorder compared to being a control participant: Odds Ratio = 1.5; 95% Confidence Interval = 1.1 to 2.1
- Insulin resistance was **not** associated with remitted major depressive disorder: Odds Ratio = 1.1; 95% Confidence Interval = 0.8 to 1.6
- Insulin resistance was positively associated with depression severity: For every unit increase in insulin resistance, depression severity score was 2.4 points higher; 95% Confidence Interval: 1.1 to 3.8.

# Is There an Insulin Resistant Subtype of Depression?

## Study 2: Insulin Resistance as Risk Factor for New Cases of Depression

- We measured insulin resistance in 601 adults without a lifetime history of depression in The Netherlands Study of Depression and Anxiety.
- Participants were given a psychiatric interview at each study visit: 0, 2, 4, 6, and 9 years after enrollment.
- Insulin resistance was measured using fasting blood glucose, waist circumference, and triglyceride-HDL ratio.



# Summary: What We Know So Far

## Depression Status


- Insulin resistance was associated with an episode of major depressive disorder status.

## Depression Characteristics

- Insulin Resistance was positively associated with depression severity and chronicity among participants in an episode of major depressive disorder.

## Risk for Developing Depression

- Triglyceride-HDL, waist circumference, and fasting plasma glucose each ratio positively predicted new cases of depression in a 9-year follow-up period among disorder-free individuals.



## Next Steps in Precision Medicine for Depression: Measuring Insulin Resistance in the Brain

---


What is the difference between central and peripheral insulin resistance?

---

Recent developments in exosome research allow us to estimate insulin resistance in the central nervous system.


---

What can central insulin resistance tell us about depression and its treatment?





# Central Insulin Resistance Associates with Depression Status and Symptoms




- A sample of 93 participants with major depressive disorder (n = 64) and healthy controls (n = 29) aged 20 – 70 from Stanford University and Mount Sinai School of Medicine.
- Insulin receptor substrate 1 was measured in exosomes to estimate insulin resistance in the nervous system.

Nasca C, Dobbin J, Bigio B, et al. Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. *Mol Psychiatry*. 2021;26(9):5140-5149.

## Preliminary Data from a Long-Term Study of Insulin Resistance and Depression

- Our current research is measuring insulin receptor substrate 1 exosomes in 2000+ adults with and without major depressive disorder and following them for 9 years.
- Preliminary data from this cohort support a positive association between central insulin resistance and depression severity in 60 subjects; 30 with depression and 30 non-depressed controls ( $p < .01$ ).



## Next Steps and Future Directions



- Examine how central insulin resistance affects depression symptoms and course over many years.
- Compare central insulin resistance and peripheral insulin resistance. Do they have a similar relationship to depression?
- Extend the panel of biomarkers measured in exosomes to assess inflammatory, neurotrophic and other mediators of depression.
- Test depression treatments related to insulin resistance in the future and measure how they change our biology.

# Acknowledgments

## **Stanford Department of Psychiatry and Behavioral Sciences:**

Natalie Rasgon, MD, PhD

Alan Schatzberg, MD

Thalia Robakis, MD, PhD

## **Stanford Department of Epidemiology and Population Health Sciences:**

Michael Baiocchi, PhD

Victor Henderson, MD, MS

Julia Simard, ScD

## **Netherland Cohort for Depression and Anxiety:**

Femke Lamers, PhD

Brenda Penninx, MD, PhD

## **Collaborators:**

Bruce McEwen, PhD

Carla Nasca, PhD

Dimitrios Kapogiannis, MD

# The Neurobiology of Insulin Resistance and Major Depressive Disorder

## Insulin resistance, an unmasked culprit in depressive disorders: Promises for interventions

Kathleen Watson <sup>a, c</sup>, Carla Nasca <sup>b</sup>, Linn Aasly <sup>a</sup>, Bruce McEwen <sup>b</sup>, Natalie Rasgon <sup>a</sup>

Show more

<https://doi.org/10.1016/j.neuropharm.2017.11.038>

Get rights and content

### Highlights

- IR is a pathological proinflammatory state underlying neuropsychiatric and somatic diseases.
- IR is part of a cascade of **allostatic load**, which is mediated in the periphery and CNS.
- **PPAR- $\gamma$  receptors**, **glutamate**, **cortisol** are among mediators of peripheral and central crosstalk underlying IR.

